ID   Mel JuSo
AC   CVCL_1403
SY   MEL-Juso; MEL-JUSO; Mel-Juso; Mel Juso; MelJuSo; MELJUSO; JuSo
DR   BTO; BTO_0001588
DR   CLO; CLO_0007676
DR   EFO; EFO_0022434
DR   EFO; EFO_0022720
DR   CLDB; cl3440
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 548
DR   BioSample; SAMN03471884
DR   BioSample; SAMN10988249
DR   cancercelllines; CVCL_1403
DR   Cell_Model_Passport; SIDM00336
DR   ChEMBL-Cells; CHEMBL3308761
DR   ChEMBL-Targets; CHEMBL1075501
DR   CLS; 300282
DR   Cosmic; 706091
DR   Cosmic; 888060
DR   Cosmic; 888835
DR   Cosmic; 897474
DR   Cosmic; 908125
DR   Cosmic; 1020272
DR   Cosmic; 1022285
DR   Cosmic; 1459306
DR   Cosmic; 1995505
DR   Cosmic-CLP; 908125
DR   DepMap; ACH-000881
DR   DSMZ; ACC-74
DR   DSMZCellDive; ACC-74
DR   EGA; EGAS00001000978
DR   GDSC; 908125
DR   GEO; GSM887309
DR   GEO; GSM888385
DR   GEO; GSM1374670
DR   GEO; GSM1670095
DR   IARC_TP53; 21493
DR   LiGeA; CCLE_674
DR   LINCS_LDP; LCL-1252
DR   PharmacoDB; MELJUSO_915_2019
DR   PRIDE; PXD011899
DR   PRIDE; PXD019519
DR   PRIDE; PXD021877
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1403
DR   PubChem_Cell_line; CVCL_1403
DR   Wikidata; Q54905064
RX   CelloPub=CLPUB00695;
RX   PubMed=2174414;
RX   PubMed=6895502;
RX   PubMed=9598804;
RX   PubMed=10766161;
RX   PubMed=11668190;
RX   PubMed=15009714;
RX   PubMed=18698037;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: ~28 hours (DSMZ=ACC-74).
CC   HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=9598804).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
CC   Sequence variation: Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012604; Zygosity=Homozygous (Cosmic-CLP=908125; DepMap=ACH-000881).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=10766161; PubMed=15009714; Cosmic-CLP=908125; DepMap=ACH-000881).
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=1.12%; South Asian=0%; European, North=63.28%; European, South=35.59% (PubMed=30894373).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
ST   Source(s): Cosmic-CLP=908125; DSMZ=ACC-74; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,9
ST   D16S539: 12,13
ST   D18S51: 15,18
ST   D19S433: 15
ST   D21S11: 29
ST   D2S1338: 20,24
ST   D3S1358: 14,17
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   D8S1179: 9,14
ST   FGA: 22
ST   Penta D: 13
ST   Penta E: 5,13
ST   TH01: 9.3
ST   TPOX: 8,10
ST   vWA: 16
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 44
//
RX   CelloPub=CLPUB00695;
RA   Guerit E.;
RT   "Generation of an ABCB5-knockout human melanoma cell line using the
RT   CRISPR/Cas9 genome editing-tool: study of ABCB5 subcellular
RT   localization by cell fractionation.";
RL   Thesis MSc (2019); University of Namur; Namur; Belgium.
//
RX   PubMed=2174414; DOI=10.1002/ijc.2910460629;
RA   Deschodt-Lanckman M.M., Vanneste Y., Loir B., Michel A., Libert A.,
RA   Ghanem G., Lejeune F.;
RT   "Degradation of alpha-melanocyte stimulating hormone (alpha-MSH) by
RT   CALLA/endopeptidase 24.11 expressed by human melanoma cells in
RT   culture.";
RL   Int. J. Cancer 46:1124-1130(1990).
//
RX   PubMed=6895502; DOI=10.1002/eji.1830111015;
RA   Johnson J.P., Demmer-Dieckmann M., Meo T., Hadam M.R., Riethmuller G.;
RT   "Surface antigens of human melanoma cells defined by monoclonal
RT   antibodies. I. Biochemical characterization of two antigens found on
RT   cell lines and fresh tumors of diverse tissue origin.";
RL   Eur. J. Immunol. 11:825-831(1981).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//
RX   PubMed=10766161;
RA   Tsao H., Zhang X., Fowlkes K., Haluska F.G.;
RT   "Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous
RT   melanoma cell lines.";
RL   Cancer Res. 60:1800-1804(2000).
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x; PMCID=PMC2586668;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
//
RX   PubMed=18698037; DOI=10.1158/1078-0432.CCR-08-0186;
RA   Reschke M., Mihic-Probst D., van der Horst E.H., Knyazev P.,
RA   Wild P.J., Hutterer M., Meyer S., Dummer R., Moch H., Ullrich A.;
RT   "HER3 is a determinant for poor prognosis in melanoma.";
RL   Clin. Cancer Res. 14:5188-5197(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//